Moving Towards Personalized Therapy in Endometrial Cancer

Description & Faculty

Treatment options for patients with advanced or recurrent endometrial cancers are rapidly evolving. Dr. Vicky Makker shares recent report from ASCO 2024 on Selinexor, a novel oral maintenance therapy for patients with TP53 wild type advanced or recurrent endometrial cancer.

	Vicky Makker, MD Section Head, Endometrial Cancer Program Director, Hematology-Medical Oncology Fellowship Training Program Memorial Sloan Kettering Cancer Center USA
	Floor Backes, MD Moderator Director of Clinical Research and Fellowship Director for the Division of Gynecologic Oncology The Ohio State University Wexner Medical Center James Comprehensive Cancer Center USA

Supported in part by

Summary


Availability:	On-Demand


Cost:	FREE

Create Account

Recommended

Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma: XPORT-042 - Trial in Progress

FREE

An Evolving Frontier: Endometrial Cancer Treatment

FREE

Immunotherapy and its impact on overall survival in patients with recurrent endometrial cancer

FREE

Mismatch repair endometrial cancer, what to do at first recurrence and beyond?

FREE

Emerging data in platinum resistance advanced ovarian cancer - Webinar

FREE

Refresher on Selecting Genetic Testing for Ovarian Cancer Treatment Decisions - Webinar

FREE

Uterine mesenchymal neoplasms: new and evolving entities - Webinar

FREE

Refresher on Selecting Genetic Testing for Ovarian Cancer Treatment Decisions

FREE

Newly Opened Phase 3 Study for Low Grade Serous Ovarian Cancer

FREE